Skip to main content

Recombinant Human Parkin Protein, CF

R&D Systems, part of Bio-Techne | Catalog # E3-160

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
E3-160-025

Key Product Details

Source

Sf 21 (baculovirus)

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human Parkin protein
Met1 - Val465

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain.

Predicted Molecular Mass

52 kDa

Activity

Reaction conditions will need to be optimized for each specific application. As supplied, Parkin has negligible E3 ligase activity as determined by the lack of autoubiquitination in an in vitro assay. Parkin ligase activity is greatly enhanced by phosphorylation.  

Formulation, Preparation and Storage

E3-160
Formulation Supplied as a solution in Tris, NaCl, Brij-35, TCEP and Glycerol.
Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.

Background: Parkin

The Parkin protein (encoded by the PARK2 gene) is an E3 ubiquitin ligase that plays an essential role in the removal of damaged mitochondria. Mutations in PARK2 are known to cause a form of Parkinson's disease known as autosomal recessive juvenile Parkinson's disease (AR-JP), and the mechanisms by which the defective Parkin protein contributes to dopaminergic cell death in this disease is an area of intense investigation. Reported substrates of the Parkin protein include BCL2, GPR37, MIRO1, MFN1, MFN2, TOMM20, USP30, and many others. The structure of the Parkin protein (an RBR-class Ubiquitin ligase) has been reported by multiple groups. These reports showed that the ligase is folded upon itself to produce an auto-inhibited state. This auto-inhibition is relieved by interactions with PINK1 kinase, which can phosphorylate both the Parkin protein and Ubiquitin at serine residue number 65, and pS65 phospho-Ubiquitin by mechanisms that are under investigation. In vitro, the Parkin protein may be activated by treatment with recombinant PINK1, or addition of low concentrations of pS65-phospho-Ubiquitin. Parkin has been reported to generate poly-Ubiquitin chains in K6, K11, K48, and K63 linkages both in vitro and in vivo

References

  1. Bingol, B. et al. (2014) Nature 510: 370.
  2. Ordureau, A. et al. (2014) Mol. Cell 56: 360.
  3. Riley, B.E. et al. (2013) Nat. Comm. 4: 1982.
  4. Saraff, S.A. et al. (2013) Nature 496: 372.
  5. Spratt, D.E. et al. (2013) Nat. Comm. 4: 1983.
  6. Trempe, J.F. et al. (2013) Science 340: 1451.
  7. Wauer T. et. al. (2015) Nature 524: 370.
  8. Wauer T. & Komander, D. (2013) EMBO J 32: 2099.

Long Name

Parkinson Disease [autosomal recessive, juvenile] 2, Parkin [PARK2], transcript variant 1

Alternate Names

AR-JP, PARK2, PDJ, PRKN

Entrez Gene IDs

5071 (Human); 50873 (Mouse); 56816 (Rat)

Gene Symbol

PRKN

UniProt

Additional Parkin Products

Product Documents for Recombinant Human Parkin Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Parkin Protein, CF

For research use only

Loading...
Loading...
Loading...